Kemme D J, Bunn P A
Division of Medical Oncology, University of Colorado Cancer Center, Denver.
Oncology (Williston Park). 1992 Feb;6(2):31-42; discussion 44, 47-8.
Mycosis fungoides and Sézary syndrome are low-grade, non-Hodgkin's lymphomas with initial cutaneous involvement. Early stage patients have a good prognosis and are commonly treated with topical agents. However, most patients eventually develop resistant skin disease or visceral disease, necessitating systemic treatment. Single agent and combination chemotherapy have resulted in high response rates, although these are short lived and not without treatment toxicities. Other modalities that have been tried with promising early results are: interferon, fludarabine, retinoids, cyclosporin, 2'-deoxycoformycin, leukapheresis, photopheresis and monoclonal antibodies (unlabeled, radiolabeled, or toxin labeled). We will discuss the available treatment options, as well as our approach to the patient with mycosis fungoides or the Sézary syndrome.
蕈样肉芽肿和塞扎里综合征是起源于皮肤的低度恶性非霍奇金淋巴瘤。早期患者预后良好，通常采用局部用药治疗。然而，大多数患者最终会发展为耐药性皮肤病或内脏疾病，需要进行全身治疗。单药化疗和联合化疗已取得较高的缓解率，尽管缓解期较短且伴有治疗毒性。其他已尝试且早期结果有前景的治疗方法包括：干扰素、氟达拉滨、维甲酸、环孢素、2'-脱氧助间型霉素、白细胞去除术、光化学疗法和单克隆抗体（未标记、放射性标记或毒素标记）。我们将讨论现有的治疗选择，以及我们对蕈样肉芽肿或塞扎里综合征患者的治疗方法。
